Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CONCERT PHARMACEUTICALS, INC. (CNCE)
|
Add to portfolio |
|
|
|
| Price: |
$3.38
| | Metrics |
| OS: |
47.9
|
M
| |
-95
|
% ROE
|
| Market cap: |
$162
|
M
| |
-196
|
% ROIC
|
|
Net cash:
|
$150
|
M
| |
$3.12
|
per share
|
|
EV:
|
$12.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($123)
|
M
| |
|
|
|
EBIT
|
($124)
|
M
| |
|
|
| EPS |
($3.25)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 32.6 | 7.9 | 1.1 | 10.5 | 143.9 | 0.2 | 66.7 | 8.6 |
| Revenue growth | 312.3% | 633.7% | -89.7% | -92.7% | 82596.0% | -99.7% | 678.1% | -66.2% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 32.6 | 7.9 | 1.1 | 10.5 | 143.9 | 0.2 | 66.7 | 8.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 87.6 | 61.6 | 59.8 | 43.1 | 30.2 | 37.0 | 28.9 | 27.5 |
| General and administrative | 22.5 | 18.9 | 20.3 | 22.9 | 21.0 | 14.4 | 13.1 | 11.7 |
| EBIT | -77.5 | -72.6 | -79.0 | -55.6 | 92.6 | -51.2 | 24.8 | -30.6 |
| EBIT margin | -237.9% | -919.3% | -7336.6% | -529.1% | 64.4% | -29406.3% | 37.1% | -356.8% |
| Pre-tax income | -80.1 | -74.8 | -78.2 | -55.4 | 95.3 | -50.7 | 24.6 | -31.7 |
| Income taxes | 0.0 | 0.1 | 0.0 | 0.3 | -0.3 | 0.0 | 0.4 | 0.0 |
| Tax rate | 0.0% | | 0.0% | | | 0.0% | 1.7% | 0.0% |
| Net income | -80.1 | -74.8 | -78.2 | -55.7 | 95.2 | -50.7 | 24.2 | -31.8 |
| Net margin | -245.7% | -946.2% | -7257.8% | -530.3% | 66.2% | -29149.4% | 36.2% | -370.3% |
| |
| Diluted EPS | ($2.33) | ($2.40) | ($3.29) | ($2.38) | $4.06 | ($2.28) | $1.09 | ($2.00) |
| Shares outstanding (diluted) | 34.4 | 31.2 | 23.7 | 23.4 | 23.4 | 22.2 | 22.3 | 15.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|